Concepedia

Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series

Giulio Metro, Gianluigi Lunardi, Chiara Bennati, P Chiarini, Isabella Sperduti, Biagio Ricciuti, Luca Marcomigni, Cinzia Costa, Lucio Crinò, Piero Floridi,

Journal of Neuro-Oncology · 2016 · 26 citations · 13 references

DOI

Concepts

References

13

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

, , +12

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 695 citations

, , +16

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015 · 638 citations · Full text

, , +13

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima et al. · Cancer Cell · 2011 · 625 citations · Full text

, , +14